Get the Stockscreener App
19.70
1.62%
-0.325
After Hours:
19.70
0.005
+0.03%
Neurogene Inc stock is traded at $19.70, with a volume of 87,974.
It is down -1.62% in the last 24 hours and down -13.31% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$20.02
Open:
$19.92
24h Volume:
87,974
Relative Volume:
0.52
Market Cap:
$281.09M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.43%
1M Performance:
-13.31%
6M Performance:
+15.18%
1Y Performance:
-45.20%
1-Day Range:
$19.40
$20.36
1-Week Range:
$19.22
$20.63
52-Week Range:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
19.70 | 285.72M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Measuring Neurogene Inc.’s beta against major indicesQuarterly Performance Summary & Daily Chart Pattern Signals - Newser
Is Neurogene Inc. forming a reversal patternQuarterly Earnings Summary & Intraday High Probability Setup Alerts - Newser
Using data models to predict Neurogene Inc. stock movementEarnings Risk Report & Free Real-Time Volume Trigger Notifications - Newser
Should you hold or exit Neurogene Inc. nowQuarterly Market Review & Community Supported Trade Ideas - Newser
Applying Elliott Wave Theory to Neurogene Inc.Quarterly Risk Review & Low Risk High Reward Ideas - Newser
Is Neurogene Inc. building a consolidation baseMarket Volume Report & Safe Entry Point Alerts - Newser
Using portfolio simulators with Neurogene Inc. includedBear Alert & Low Risk High Win Rate Stock Picks - Newser
Has Neurogene Inc. formed a bullish divergence2025 Technical Overview & Stepwise Swing Trade Plans - Newser
Is This a Bottoming Phase for Neurogene Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
Using economic indicators to assess Neurogene Inc. potential2025 Volume Leaders & Accurate Technical Buy Alerts - Newser
How to recover losses in Neurogene Inc. stockExit Point & Smart Investment Allocation Insights - Newser
Will Neurogene Inc. bounce back from current support2025 Investor Takeaways & Community Consensus Picks - Newser
Chart based exit strategy for Neurogene Inc.2025 Performance Recap & Stepwise Trade Execution Plans - Newser
What risks could impact Neurogene Inc. stock performanceTrade Volume Summary & Long-Term Growth Plans - Newser
Order Flow Trends Show Accumulation in Neurogene Inc.Weekly Risk Summary & Community Trade Idea Sharing - 더경남뉴스
Neurogene Inc. Reversal Rally May Surprise BearsJuly 2025 Intraday Action & Weekly Consistent Profit Watchlists - beatles.ru
What is Neurogene Inc.’s valuation compared to sectorProduct Launch & Safe Capital Preservation Plans - theviewers.co.kr
Ranking Neurogene Inc. among high performing stocks via toolsGap Up & Expert Curated Trade Setups - Newser
How moving averages guide Neurogene Inc. tradingQuarterly Market Summary & Weekly Stock Breakout Alerts - Newser
Published on: 2025-08-21 05:11:36 - newsyoung.net
Published on: 2025-08-20 16:31:54 - 더경남뉴스
Quantitative breakdown of Neurogene Inc. recent moveTrade Exit Report & Growth Focused Entry Reports - Newser
Has Neurogene Inc. found a price floorJuly 2025 Opening Moves & Weekly Momentum Stock Picks - Newser
Visual analytics tools that track Neurogene Inc. performance2025 Support & Resistance & Fast Gain Swing Alerts - Newser
What MACD signals say about Neurogene Inc.2025 AllTime Highs & Technical Analysis for Trade Confirmation - Newser
Watch for Bullish Crossover in Neurogene Inc.Quarterly Profit Report & Weekly Stock Performance Updates - 선데이타임즈
How to read the order book for Neurogene Inc.Weekly Loss Report & Reliable Trade Execution Plans - Newser
How to monitor Neurogene Inc. with trend dashboardsWeekly Stock Summary & Community Driven Trade Alerts - Newser
Momentum Indicator Shows Bearish Divergence in Neurogene Inc.Market Performance Summary & Weekly High Return Forecasts - 선데이타임즈
Sentiment analysis tools applied to Neurogene Inc.Market Movement Recap & Real-Time Buy Zone Alerts - Newser
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):